SOAT1 and colorectal adenocarcinoma: Although dysregulated JAK–STAT signaling represents an attractive therapeutic target for modulating the immune responses [33], JAKs inhibitors have shown limited clinical utility in solid tumours, including patients with refractory colorectal adenocarcinoma [34, 35].